Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CuraGen Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients ages \> 18 yrs
Patients undergoing high dose chemotherapy with or without radiation therapy treatment as conditioning for autologous hematopoietic stem cell transplantation. The conditioning regimens include at least one of the following: high dose melphalan (Mel 200), busulfan, or etoposide, with or without total body irradiation.
Patients with Karnofsky performance scores \> or = 70%
Informed consent for participation in study
You may not be if
Patients who weigh \< 33 kg
Premenopausal female patients who are pregnant, lactating or are likely to become pregnant
Patients with active medical conditions that preclude autologous hematopoietic stem cell transplantation
Patients diagnosed with active acquired immunodeficiency syndrome (AIDS) or Hepatitis B/C
Patients with known hypersensitivity to recombinant protein therapeutics
Patients who have taken CG53135-05, palifermin or other investigational drugs in the past 30 days
Patients who have untreated symptomatic dental infection
Patients with a history of sensitivity or allergy to E. coli-derived products
Patients with WHO Grade 3 or 4 oral mucositis (OM)
Clareo Health | Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
